Foresite Capital β 2024 Investments
9 investments dated 2024 Β· listed companies and verified rows first Β· show all
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)Mark Bradley(Chief Development Officer)Kolbot By(SVP, Head of Technical Operations)Jack Danilkowicz(Chief Commercial Officer)JΓΆrn Drappa(Chief Medical Officer)David M Goldstein(Chief Scientific Officer)
Board seatJames TananbaumΒ· per SEC Form D
Co-investorsNextech InvestOrbiMedSamsara BioCapitalSR One Capital ManagementvenBio PartnersWestlake Village BioPartners+1 more
Denali Therapeutics develops therapeutics for neurodegenerative diseases.
BiotechHealthtechMedical DevicesSan Francisco, US
Marc Tessier-Lavigne(Director)Ryan Watts(Executive Officer, Director)Alexander O. Schuth(Executive Officer)Carole Ho(Executive Officer)Steve E. Krognes(Director)
BoardDavid P. Schenkein(Director)in
Co-investorsARCH Venture PartnersEcoR1 CapitalF-Prime CapitalGV (Google Ventures)
Improving patients' lives by accelerating development and commercialization of medicines that matter.
BiotechCambridge, US
Sanjiv K. Patel(Executive Officer, Director)Donald A. Bergstrom(Executive Officer)Thomas Catinazzo(Executive Officer)Peter Rahmer(Executive Officer)Sekar Kathiresan(Director)Douglas S. Ingram(Director)
Co-investorsCommonweal VenturesCurie.Bio
Seaport Therapeutics develops therapeutics and medicines.
BiotechMental HealthBoston, US
Daphne Zohar(Founder, CEO and Board Member)inMichael Chen(Executive Officer)Lana Gladstein(Executive Officer)Antony Loebel(Executive Officer)Eric Green(Executive Officer)
BoardJames I. Healy(Director)
Co-investorsARCH Venture PartnersHAWKTAILPureTech HealthSofinnova Ventures
Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.
AI & Machine LearningBiotechWatertown, US
Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)Robert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)Matthew Patterson(Director)Scott Biller(Director)
Board seatMichael RomeΒ· per SEC Form D
Co-investorsAtlas VentureThe Column GroupARCH Venture PartnersDecheng Capital
BiotechWoburn, US
Feng Xuan(Executive Officer, Director)Peng Yin(Director)John Wu(Executive Officer)Wen Chan(Director)Michael Natan(Executive Officer, Director)
BoardDavid Singer(Director)
Board seatVikram BajajΒ· per SEC Form D
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)Kenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)Bernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Co-investorsOrbiMedSamsara BioCapitalTCG CrossoverThird Rock VenturesvenBio PartnersVida Ventures
Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.
BiotechMedical DevicesLower Gwynedd, US
Joseph Erhardt(Executive Officer)Peter Lebowitz(Executive Officer, Director)
BoardArjun Goyal(Director)inOtello Stampacchia(Director)inFrancesco Draetta(Director)in
Co-investorsAndreessen HorowitzVida Venturesabrdn plcBiotechnology Value FundHillhouse InvestmentOmega Funds+1 more
Xaira develops AI and machine learning tools for drug discovery and protein design, serving pharmaceutical and biotech companies.
AI & Machine LearningBiotechMedical DevicesSouth San Francisco, US
Hetu Kamisetty(Founder)Marc Tessier-Lavigne(Founder)inDr. Ci Chu(Chief Discovery Officer)Dr. Bo Wang(Chief AI Scientist)Dr. Ian McCaffery(SVP, Translational Science and Early Clinical Development)
Co-investorsARCH Venture PartnersBreyer CapitalF-Prime CapitalLongwood FundMenlo VenturesNew Enterprise Associates (NEA)+1 more
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.